BioSpace News Archive

Spectrum Pharmaceuticals, Inc. today announced the commercial availability of ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues).

SK bioscience announced that Dr. Harry Kleanthous, formerly Senior Program Officer in Global Health at the Bill & Melinda Gates Foundation, has joined the Company as Executive Vice President of Vaccine R&D Strategy and External Innovation.

DNAnexus, Inc., the leader in biomedical informatics and data management, announced the appointment of Jeff Margolis, a seasoned healthcare information technology executive and current Senior Advisor for Blackstone, to its Board of Directors.

Elpiscience Biopharmaceuticals, Inc. today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12.

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will participate in two October 2022 conferences.

Novan, Inc., EPI Health, a Novan Company, and MC2 Therapeutics announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.

RenovoRx, Inc. today announced that the Company’s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET. To register for the event please visit RenovoRx Fireside Chat Registration.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced positive data demonstrating the impact of PAD Technology™ in WYNZORA® Cream in three posters featured at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.